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Background: Medication overuse headache (MOH) has been recognized as an important problem in headache
patients although the pathophysiological mechanisms remain unclear. The diagnosis of MOH is based on clinical
characteristics defined by the International Headache Society. The aim was the evaluation of the diagnostic criteria
of MOH in a mixed population of chronic pain patients to gain information about the prevalence and possible
associations with MOH.
Methods: Data of all patients referred to the interdisciplinary pain clinic at the University Hospital of Zurich
between September 2005 and December 2007 were retrospectively analyzed. Demographic data (age, sex, history
of migration), as well as data about duration of pain disease, category of pain disease (neurological, psychiatric,
rheumatologic, other), use of medication, history of trauma, and comorbidity of depression and anxiety have
been collected.
Results: Totally 178 of 187 consecutive chronic pain patients were included in the study. A total of 138 patients
(78%) used analgesics on 15 or more days per month. Chronic headache was more prevalent among patients
with analgesic overuse (39.8%) than without analgesic overuse (18%). The prevalence of MOH was 29%. The odds
ratio (OR) for a patient with medication overuse to have chronic headache was 13.1 if he had a history of primary
headache, compared to a patient without a primary headache syndrome. Furthermore, history of headache
(OR 2.5, CI [1.13;5.44]), history of migration (OR 2.9, CI [1.31;6.32]) and comorbid depression (OR 3.5, CI [1.46;8.52])
were associated with overuse of acute medication, in general.
Conclusions: Primary headaches have a high risk for chronification in patients overusing analgesics for other pain
disorders. Whereas history of headache, history of migration and comorbidity of depression are independentely
associated with analgesic overuse in this group of patients.
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Medication overuse headache (MOH) is considered to be
an important problem among headache patients world-
wide with an estimated prevalence of 1–1.5% in the gen-
eral population [1-5]. Studies mainly performed in tertiary
care headache centers found that migraineurs and, to a
lesser extent, patients with tension type headache are at* Correspondence: konrad.maurer@usz.ch
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reproduction in any medium, provided the origrisk for worsening of their headache under regular intake
of acute relief medication [6]. Although MOH is prevalent
in patients of all age groups, a considerable part of the
working population is affected. MOH therefore might
have an important socioeconomical impact.
MOH is a concept based on clinical observations first
described in the late 1950s [7]. The underlying mecha-
nisms are still unclear [8]. Recent findings suggest that
the regular intake of an analgesic substance might lead
to changes in different neurobiochemical systems; e.g.
the serotoninergic system is modulated by the intake of
different classes of analgesics which will lead to altera-
tions of the antinociceptive serotoninergic pathway andr. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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involve the NMDA-receptor [17], the opioid- system [18],
and alterations in membrane transduction [19].
New diagnostic criteria vor MOH were introduced in
2006 [20] (see Table 1 for diagnostic criteria). Popula-
tion-based studies have identified possible risk factors
for the development of chronic headache, such as age,
female gender, low socioeconomic status, non-married
civil status, obesity, snoring, comorbid musculoscele-
tal pain, head and neck injury, and stressful life events
[21,22]. This has raised the question whether chronic
headache is the consequence or the cause of overused
analgesics [21,23]. The development of “de novo” MOH
in patients overusing analgesics would establish this
causative relationship, however, prospective studies on
that topic are missing. Patients taking analgesics for
chronic pain - other than headache - represent an inter-
esting population to examine such a context. Previous
studies, using other than the ICHD-II-Appendix criteria
for the definition of MOH, showed conflicting results
regarding new onset headache under medication over-
use [24-28].
The objective of the present study was to examine the
prevalence of MOH as defined in the new ICHD-II-
Appendix criteria in a population of patients with chro-
nic pain different than headache. Our hypothesis was that
chronic headache would be more prevalent in patients
with analgesic overuse (AO), especially when additionaly
suffering from primary headaches, such as migraine or
tension type headache.
Methods
The interdisciplinary pain clinic at the University Hos-
pital of Zurich is a tertiary referral center for chronic
pain patients. Participating specialists are an anesthesio-
logist, a neurologist, a psychiatrist and a rheumatologist.
Patients were referred directly by General Practitioners
and Specialists from the whole region of Zurich without
selection bias from any of the participating specialists.Table 1 Overview of the different criteria for Medication over
ICHD-I ICHD-II ICHD
IHS 1988 IHS 2004 Silbe
Comment not defined Different entities for different
substances
Elimi
A Headache1 > 15 days/month Head




for ≥ 3 months for >
C Headache developed or worsened Head




1 Headache characteristics defined for different substances.
2 ≥ 10 days/month for ergotamines, triptans, opioids or combination analgesics; ≥ 1Upon referral, every patient is examined by each spe-
cialist separately in the course of one week. The exa-
mination consists of a careful and pain-specific history
taking and a physical examination. Headache diagnosis
of all affected patients are made by a well trained neurolo-
gist (PS) according to ICHD-II and ICHD-II-Appendix
criteria regarding MOH, respectively [20,29]. At the end
of the week patients are dicussed in a meeting to elaborate
a comprehensive diagnostic worksheet and to provide a
treatment plan, based on clinical findings and patho-
physiological considerations. After informing the patient
about the results, a comprehensive report is written to the
referring general practicioner or specialist.
The study was approved by the local ethical committee
and conducted according to the principles of the Declar-
ation of Helsinki. All patients had signed an informed
consent to allow subequent use of their data for stu-
dy purposes. For the study period (September 2005 to
December 2007) data were collected from the compre-
hensive reports retrospectively. If necessary, additional de-
mographic data, information about pain symptoms, pain
scores, mood disturbances and drug intake, or specialists’
examination protocols was taken from the patients charts.
Data collection
Data of all patients referred to the interdisciplinary pain
clinic were screened. Exclusion criteria were: headache as
the sole pain symptom; incomplete examination (defined
as examination by less than 3 specialists) and missing data
on medication intake. The information collected for this
study included demographic data regarding age; gender;
history of migration (defined as having a mother tongue
other than one of the four Swiss national languages:
Swiss-German, French, Italian, Rumantsch); duration
(years) of pain suffering; history of head and/or neck trau-
ma, and use and type of acute medication. The disorders
were categorized into: “neurologic”, “rheumatologic”, “psy-
chiatric” and “other”. Headache diagnosis and comorbidity
of “depression” and “anxiety” were additionally recorded.use headache (MOH)
-II revised ICHD-II Appendix
rstein et al. 2005 Olesen et al. 2006
nation of headache characteristics Elimination of criterion D
ache≥ 15 days/month Headache≥ 15 days/month
ance overuse ≥ 10/152
month
Substance overuse ≥ 10/152
days/month
3 months for > 3 months
ache developed or worsened Headache developed or worsened
ution within 2 months after
rawal
n.a.
5 days/month for simple analgesics (or combination of any, ICHD-II Appendix).
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two subgroups “analgesic overuse (AO)” and “no analge-
sic overuse (noAO)”, in analogy to the criteria for medi-
cation overuse headache (MOH) defined by the ICHD-II
Appendix (10 or more days for triptans and opioids, 15
or more days for analgesics). Age, gender, years of pain
suffering, history of migration, history of headache, his-
tory of accident (subsequently refered to as “accident”),
depression and anxiety were defined as possible asso-
ciated factors for analgesic overuse.
Statistical analysis
For the analysis of the primary hypotheses, Fisher’s exact
test comparing binary variables was performed. For the
univariate analysis of associations the Fisher-Test was
applied for binary and nominable variables. For conti-
nous variables, a t-test was performed for normally dis-
tributed and a Mann–Whitney-U-Test for not normally
distributed data. For all significant factors, OR with 95%-
confidence interval was provided. A significance level of
p < 0.05 was defined. For multiple testing Bonferroni-
corrected p-values were used. Regarding associations for
medication overuse, a multiple logistic regression was per-
formed with all factors significant at univariate analysis,
and OR with 95%- confidence interval provided.
Results
Data of 187 consecutive patients were screened and 178
patients were included in the study. Nine patients were
excluded: in seven patients headache was the only pain
disease, one patient had an incomplete examination and
one patient had incomplete data regarding medication
intake. Five patients were not evaluated by the psychia-
trist and were therefore excluded from classification of
disease categories and analysis of depression and anxiety
as associated factors for analgesic overuse.
Demographic and clinical characteristics of the overall
study population
Of the 178 patients, 91 (51%) were female. The mean
age was 46 ± 13 years (range 18 to 81 years). A total ofTable 2 Demographic data of all the patients, as well as the s
Overall population A
n = 178
Age (y, mean ± SD) 46 ± 13
Sex male/ female 85/ 93
History of migration (n) 111
Duration of pain disorder (y) 7.8 ± 9.2
Accident (n) 53
Depression (n) 82
Anxiety (n) 22112 (63%) patients had a history of migration. The mean
duration of pain suffering was 7.8 ± 9.2 years (range 0 to
50 years) (Table 2). The diagnostic category was rheuma-
tologic in 146 patients, psychiatric in 138, neurologic in
114; and 17 had an “other” diagnostic category. The cu-
mulative number of diagnostic categories per patient
was 4 in 3% of the patients, 3 in 48%, 2 in 35% and only
one category in 14%. At the time of the assessment 92
patients (52%) reported to have headache, whereas 57
patients (32%) had headache on ≥ 15 days per month.
Migraine was the most frequent headache type, diagnosed
either as the only headache type or in combination with
other headache types in a total of 63 (35%) patients. Ten-
sion type headache was found in 16 patients (9%).
Use of acute medication
Only 28 of 178 (16%) patients did not take any acute
medication at all and 12 (7%) patients took analgesics on
less than 15 days per month. NSAIDs were the most
commonly used drugs (93 patients, 62%), followed by
opioids (85 patients, 57%) and paracetamol (77 patients,
51%). Triptans and ergotamins drugs were consumed by
8 (5%) and 1 (1%) patients respectively. Out of the 138
patients overusing analgesics, 131 (95%) had a daily in-
take. Of them 56 (41%) took one analgesic, 52 (38%)
took two different types, 27 (20%) three different types
and 3 (2%) patients four different types on analgesics.
Characteristics of subgroups “analgesic overuse (AO)” and
“no analgesic overuse (noAO)”
Of 178 patients, 138 (78%) were overusing analgesics as
defined by criterion B in the ICHD-II-Appendix classifi-
cation [20]. In the subgroups “with” and “without” anal-
gesic overuse mean age was 46 ± 12 years, and 42 ± 14
respectively, gender distribution was 51% and 50%, and
mean duration of pain suffering was 7.8 ± 8.9 years and
8.0 ± 9.9 years, respectively. The percentage of patients
with a history of migration was higher in the AO
subgroup with 69%, as compared to noAO with 43%
(p = 0.012), and to the overall population (63%). While
31% of patients with analgesic overuse reported a previousubgroups with and without analgesic overuse
nalgesic overuse No analgesic overuse p-value
n = 138 n = 40
46 ± 12 42 ± 14 ns
65/ 73 20/ 20 ns
95 16 0.012
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analgesic overusers (28%) and the overall sample popula-
tion (30%). In patients with AO 59% had been diagnosed
with anxiety and/or depression, in the noAO 20% only.
Headache characteristics
While 62 patients in the sample reported chronic head-
aches (CDH: headaches on 15 or more days per month),Figure 1 Patient population.a total of 52 patients fullfilled the ICHD-II-Appendix
criteria [20] for medication overuse headache (for an
overview see Figure 1). This is 38% of the patients over-
using analgesics (n = 138) and 29% of all patients with
chronic pain in the sample (n = 178). There were 3 pa-
tients with CDH in the group with analgesic overuse who
did not fullfill criterion C (see Table 1), and 7 patients who
where not overusing analgesics. Therefore, the prevalence
Table 3 MOH and history of primary headache or migraine
a) OR 13.1, CI [5.52; 31.01]
History of primary HA
yes no
MOH
yes 43 9 52
no 23 63 86
63 75 138




yes 35 17 52
no 20 66 86
55 83 138
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138) and 18% (=7/40) in the noAO group. The propor-
tions of patients with a history of migraine and/or other
primary headaches (i.e. tension type headache) were for
MOH 67%, for AO only (without MOH) 27%, and for
noAO 25% (see Figure 1). The prevalence of migraine was
67% (= 35/52) in the MOH patients, 23% (= 20/86)
in the AO only group, and 20% (= 8/40) in the noAO
group. The probability (OR) was 13.1 (CI [5.52; 31.01])
times higher for patients overusing analagesics to develop
MOH when there was a history of primary headaches (see
Table 3), and 6.8 times higher when they suffered from
migraine.
Associated factors for pain medication overuse
History of previous headache, history of migration, and
comorbid depression were identified as significantly as-
sociated in the univariate analysis. The multiple logistic
regression resulted in odds ratios of 2.5 (CI [1.13;5.44])
for a history of primary headache, 2.9 (CI [1.31;6.32]) for
a history of migration, and 3.5 (CI [1.46;8.52]) for co-
morbid depression (see Table 4).Table 4 Associated factors with chronification of headache
p-value p-value after
Bonferroni correc
Age Age + 10 years 0.09 0.703
Sex male/ female 0.86 1.000
Duration of pain disorder 0.76 1.000
History of migration 0.0015 0.012




Table 4 shows results of the univariate analysis of different factors. P-values and p-v
confidence interval are calculated only when p-values were significant. Also, odds r
history of headache or depression.Discussion
So far, five studies on MOH in chronic pain patients
have been published [24-28]. Lance et al. found that 24
of 89 patients in a rheumatology clinic had headache on
4 to 28 days per month while taking more than 14
tablets per week; no significant difference in headache
frequency between those taking more or less than 14
tablets per week was found [26]. Bowdler et al. reported
6 patients complaining of chronic headache out of 1411
consecutive cases (0.4%) in an anesthesiological pain cli-
nic, of which 140 (9.9%) had regular non-opioid anal-
gesic intake [25]. In 28 patients taking opioids regularly
for bowel motility control after total colectomy, Wilkin-
son et al. found 8 patients with daily intake of opioids;
while two of them suffered from chronic daily headache
and both reported a history of previous migraine [27].
Bahra studied a population of 111 patients in a rheuma-
tology clinic, identifying 103 patients with regular anal-
gesic use; of those, 8 (7.6%), all migraineurs, suffered
from CDH [24]. Finally, another population from a rheu-
matolgy clinic was studied by Williams et al., finding
that 14 of 114 (12%) patients suffered from chronic
daily headache, whereas 9 (8%) patients met the criteria
for problable MOH according to ICHD-II revised cri-
teria [28,30]. However, all those studies have been using
diagnostic criteria other than current ICHD-II-Appendix
definition for MOH, and therefore comparison with our
data is difficult.
The prevalence of 29% for MOH in our pain popula-
tion is higher than previously reported. Different reasons
may explain our finding. First, ICHD-II-Appendix cri-
teria enable more patients to be diagnosed with MOH at
the time of the examination. The rationale behind this is
to increase awareness for the problem and to allow more
patients to benefit from specific treatment [20]. Reports
of underestimation of MOH in clinical practice support
these arguments [3,24]. Due to the retrospective nature
of our study, the prevalence of MOH might have beention





3.29 [1.51,7.36] 2.89 [1.13,5.44]
3.31 [1.51,7.46] 2.48 [1.31,6.32]
–
4.51 [1.85,12.25] 3.52 [1.46,8.52]
–
alues after bonferroni correction are listed. Odds ratios and the 95%
atios after multiple log. Regression are listed for age + 10 years, migration,
Wanner Schmid et al. The Journal of Headache and Pain 2013, 14:4 Page 6 of 7
http://www.thejournalofheadacheandpain.com/content/14/1/4overestimated because of incomplete information on the
timing of headache chronification and beginning of me-
dication overuse (criterion C of the definition, [20]).
Also, our population consisted of patients referred to a
tertiary pain clinic because of long-standing and com-
plex pain problems, as reflected by the high number of
cummulative diagnostic categories in the majority of ca-
ses. In Switzerland, healthcare system allows free access
to specialists for most people. Patients may consult more
than one specialist for their complex health problem,
leading to prescription of analgesics by different doctors
without knowledge of the patients current drug treat-
ment. Many of the analgesics taken are even over the
counter (OTC), what represents another risk factor for
uncontrolled analgesic intake. Due to the retrospective
nature of our study we have to take into account meth-
odological limitations. These limitations apply to adequacy
and bias of data collection due to quality of recorded in-
formation and inadequacy of patient’s reports, as already
mentioned. However, more inclusive criteria would pro-
duce more false positive cases, i.e. patients with headache
chronification unrelated to medication overuse, will be
diagnosed with MOH [31]. Hence, some researchers have
challenged the hypothesis of medication overuse leading
to chronic hedache. They criticized that the primary cli-
nical observation for the concept of MOH, i.e. improve-
ment of headache after discontinuation of medication
overuse, has never been demonstrated in a placebo-
controlled trial, and has yet to be formally proved [32]. On
the other hand, the fact that a subset of patients does im-
prove in their headache pattern after withdrawal cannot
be disregarded. The conclusion that we can draw from
this controversy is that in some headache patients the
headache will chronify as a consequence of the medication
overuse, while in others the chronification is caused by
other factors.
Comorbid depression, history of migration, history of
headache and have been identified as independently as-
sociated factors for analgesic overuse in general, this is
in line with previous studies [33-35]. The association of
having a history of primary headaches among the MOH
patients, is in line with other studies. This accounts es-
pecially for migraine. In contrast to Radat et al., we found
no significant correlation between anxiety and medication
overuse [36]. However, psychiatric evaluation was not
done using standardized questionnaires.
Conclusions
In summary, our study showed that MOH might be
more prevalent in chronic pain patients than previously
suggested. ICHD-II-Appendix criteria proved to be a
good screening instrument to detect MOH, leading in-
stantly to the first and most important therapeutic step
of drug withdrawal. Our data also suggest that headachechronification may be associated with other factors than
medication overuse. Finally, chronic pain patients are
a population at risk for developping analgesic overuse;
therefore, careful recording of drug intake is mandatory
in these patients, especially in the ones with a history
of migration, a history of headache and/or depression.
There is no simple answer as to how to treat those pa-
tients correctly. Whether to stay i.e. untreated on low
back pain instead of developping chronic headaches is
an issue, which has to be discussed in depth with the in-
dividual patient at risk, and a clear aim of the treatment
should be defined in any case.Competing interests
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